Chronic Lymphocytic Leukemia

SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.

SAN DIEGO — In this video, Jennifer A. Woyach, MD, discusses a phase 3 randomized trial comparing pirtobrutinib to idelalisib or bendamustine plus rituximab for chronic lymphocytic leukemia pretreated with Bruton tyrosine kinase inhibitor.

SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.

Jennifer A. Woyach, MD, has been named the new director of the division of hematology at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.

Patients with chronic lymphocytic leukemia who achieved undetectable minimal residual disease achieved significantly longer PFS than patients with minimal residual disease, according to results of a systematic review and meta-analysis.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.

Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, improved survival compared with standard chemoimmunotherapy for certain adults with leukemia, according to a topline data announcement.

In a video interview, Matthew Cortese, MD, MPH, discusses how AI could transform the treatment landscape for CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses the importance of long-term monitoring in CLL care.